Beam updates portfolio, operating highlights

 Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

Lilly Acquires Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Cardiovascular Programs for up to $600 Million in Combined Upfront Payment, Equity Investment and Potential Future Development-Stage Payments

GMP Operations Initiated at Beam's North Carolina Manufacturing Facility

Strong Balance Sheet Provides Anticipated Operating Runway into the Second Half of 2026

https://www.globenewswire.com/news-release/2023/11/08/2776008/0/en/Beam-Therapeutics-Reports-Pipeline-and-Business-Updates-and-Third-Quarter-2023-Financial-Results.html